Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCNB2 | O95067 | 2/20 | 0.63 |
| ▸ | CDK1 | P06493 | 2/20 | 0.63 |
| ▸ | CCNB1 | P14635 | 2/20 | 0.63 |
| ▸ | CCNB3 | Q8WWL7 | 2/20 | 0.63 |
| ▸ | GSK3B | P49841 | 1/20 | 0.63 |
| ▸ | CDK5 | Q00535 | 1/20 | 0.63 |
| ▸ | CDK5R1 | Q15078 | 1/20 | 0.63 |
| ▸ | RIPK1 | Q13546 | 18/20 | 0.59 |
| ▸ | NPC1 | O15118 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31160491 | 0.82 | RIPK1 (0.46) | CCNB2CDK1CCNB1CCNB3GSK3B | |
| SCHEMBL26053438 | 0.80 | RIPK1 (0.71) | CCNB2CDK1CCNB1CCNB3RIPK1 | |
| SCHEMBL1778505 | 0.78 | RIPK1 (0.74) | CCNB2CDK1CCNB1CCNB3GSK3B | |
| SCHEMBL10014915 | 0.78 | CCNB2 (1.00) | CCNB2CDK1CCNB1CCNB3GSK3B | |
| SCHEMBL1780991 | 0.76 | CYP19A1 (0.66) | CCNB2CDK1CCNB1CCNB3RIPK1 | |
| SCHEMBL24655593 | 0.74 | RIPK1 (0.71) | CCNB2CDK1CCNB1CCNB3GSK3B | |
| SCHEMBL5604499 | 0.74 | RIPK1 (0.67) | CCNB2CDK1CCNB1CCNB3RIPK1 | |
| SCHEMBL1780494 | 0.74 | RIPK1 (0.71) | CCNB2CDK1CCNB1CCNB3RIPK1 | |
| SCHEMBL7892114 | 0.74 | RIPK1 (0.71) | CCNB2CDK1CCNB1CCNB3GSK3B | |
| SCHEMBL5907874 | 0.74 | RIPK1 (0.71) | CCNB2CDK1CCNB1CCNB3GSK3B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7943616-B2 | Protein kinase inhibitors; astham; psoriasis; antiinflammatory agents; inflammatory bowel disorders | AVENTIS PHARMACEUTICALS INC. (US) | 2011-05-17 | — | — | US | disclosed |
| US-7943616-B2 | Protein kinase inhibitors; astham; psoriasis; antiinflammatory agents; inflammatory bowel disorders | AVENTIS PHARMACEUTICALS INC. (US) | 2011-05-17 | — | — | US | disclosed |
| EP-2233486-A1 | Azaindoles | Aventis Pharma Limited (GB) | 2010-09-29 | — | — | EP | disclosed |